免疫(纳斯达克：IMTX)和蚝点医药(纳斯达克：OYST)关键分析

Immatics (NASDAQ:IMTX – Get Rating) and Oyster Point Pharma (NASDAQ:OYST – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Profitability

This table compares Immatics and Oyster Point Pharma's net margins, return on equity and return on assets.

Immatics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

36.6% of Immatics shares are owned by institutional investors. Comparatively, 86.3% of Oyster Point Pharma shares are owned by institutional investors. 17.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Immatics and Oyster Point Pharma, as provided by MarketBeat.com.

Immatics currently has a consensus target price of $26.00, suggesting a potential upside of 190.18%. Oyster Point Pharma has a consensus target price of $19.00, suggesting a potential upside of 313.94%. Given Oyster Point Pharma's higher probable upside, analysts clearly believe Oyster Point Pharma is more favorable than Immatics.

Earnings & Valuation

This table compares Immatics and Oyster Point Pharma's top-line revenue, earnings per share and valuation.

Oyster Point Pharma has lower revenue, but higher earnings than Immatics. Oyster Point Pharma is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Summary

Immatics beats Oyster Point Pharma on 9 of the 14 factors compared between the two stocks.

Immatics Company Profile (Get Rating)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Oyster Point Pharma Company Profile (Get Rating)

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.